{"id":2354,"date":"2026-02-20T16:33:14","date_gmt":"2026-02-20T16:33:14","guid":{"rendered":"https:\/\/economicowl.com\/?p=2354"},"modified":"2026-02-20T16:33:15","modified_gmt":"2026-02-20T16:33:15","slug":"eli-lilly-acquires-orna-to-expand-cancer-technology","status":"publish","type":"post","link":"https:\/\/economicowl.com\/?p=2354","title":{"rendered":"Eli Lilly Acquires Orna to Expand Cancer Technology"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\"><strong>Deal adds in-body cell engineering platform<\/strong><\/h2>\n\n\n\n<p>Eli Lilly announced an agreement to acquire Orna Therapeutics for up to $2.4 billion in cash, advancing its push into next-generation cancer and immunology treatments. The transaction gives the U.S. drugmaker access to a technology designed to enable patients\u2019 own cells to generate therapies directly inside the body, avoiding the need for cell extraction and reinfusion.<\/p>\n\n\n\n<p>Lilly shares rose more than 3% in early trading following the announcement, reflecting investor optimism around the company\u2019s continued diversification strategy.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>In vivo approach to CAR-T therapy<\/strong><\/h2>\n\n\n\n<p>Orna is developing treatments based on circular RNA combined with proprietary lipid nanoparticles. Its lead program, ORN-252, is an early-stage chimeric antigen receptor T-cell therapy that targets CD19, a receptor commonly associated with certain blood cancers.<\/p>\n\n\n\n<p>Unlike conventional CAR-T approaches, which require immune cells to be removed from patients and modified in specialized laboratories, Orna\u2019s platform aims to engineer those cells directly within the patient\u2019s body. This in vivo method could simplify treatment delivery and potentially lower costs and complexity.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Strategic fit with Lilly\u2019s oncology ambitions<\/strong><\/h2>\n\n\n\n<p>Analysts see the acquisition as a way for Lilly to broaden its technical capabilities in oncology and immunology. The company has been actively expanding beyond its market-leading obesity drugs, building a portfolio that spans cancer, inflammatory diseases, eye disorders, and genetic medicine.<\/p>\n\n\n\n<p>The deal adds to a series of transactions completed in recent months as Lilly seeks to reduce reliance on a single therapeutic category and establish a longer runway for growth.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>High potential balanced by development risk<\/strong><\/h2>\n\n\n\n<p>While the technology offers significant promise, analysts cautioned that it remains unproven at scale. Orna\u2019s programs are still in early development, and large clinical trials will be needed to validate safety and efficacy.<\/p>\n\n\n\n<p>The competitive landscape is also crowded. Several pharmaceutical companies already market CAR-T therapies and have invested heavily in next-generation platforms, raising the bar for differentiation and clinical success.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Part of a broader deal-making push<\/strong><\/h2>\n\n\n\n<p>The Orna acquisition follows a recent agreement with a Chinese biotechnology partner to jointly develop oncology and immunology treatments, a deal that includes an upfront payment and significant milestone-based compensation.<\/p>\n\n\n\n<p>Together, these moves underscore Lilly\u2019s intent to leverage its financial strength to secure emerging technologies that could define future treatment paradigms, even as it continues to dominate the fast-growing obesity drug market.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Deal adds in-body cell engineering platform Eli Lilly announced an agreement to acquire Orna Therapeutics for up to $2.4 billion in cash, advancing its push into next-generation cancer and immunology treatments. The transaction gives the U.S. drugmaker access to a technology designed to enable patients\u2019 own cells to generate therapies directly inside the body, avoiding [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":2349,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[106],"tags":[],"tmauthors":[119],"ppma_author":[115],"class_list":{"0":"post-2354","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eli Lilly Acquires Orna to Expand Cancer Technology - Economic Owl<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/economicowl.com\/?p=2354\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly Acquires Orna to Expand Cancer Technology - Economic Owl\" \/>\n<meta property=\"og:description\" content=\"Deal adds in-body cell engineering platform Eli Lilly announced an agreement to acquire Orna Therapeutics for up to $2.4 billion in cash, advancing its push into next-generation cancer and immunology treatments. The transaction gives the U.S. drugmaker access to a technology designed to enable patients\u2019 own cells to generate therapies directly inside the body, avoiding [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/economicowl.com\/?p=2354\" \/>\n<meta property=\"og:site_name\" content=\"Economic Owl\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-20T16:33:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-20T16:33:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/eli-lilly-acquires-orna-to-expand-cancer-technology.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"667\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sarah Romano\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sarah Romano\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/economicowl.com\/?p=2354#article\",\"isPartOf\":{\"@id\":\"https:\/\/economicowl.com\/?p=2354\"},\"author\":{\"name\":\"Sarah Romano\",\"@id\":\"https:\/\/economicowl.com\/#\/schema\/person\/47aea2855bc9394f42185505c66c542c\"},\"headline\":\"Eli Lilly Acquires Orna to Expand Cancer Technology\",\"datePublished\":\"2026-02-20T16:33:14+00:00\",\"dateModified\":\"2026-02-20T16:33:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/economicowl.com\/?p=2354\"},\"wordCount\":395,\"publisher\":{\"@id\":\"https:\/\/economicowl.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/economicowl.com\/?p=2354#primaryimage\"},\"thumbnailUrl\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/eli-lilly-acquires-orna-to-expand-cancer-technology.jpg\",\"articleSection\":[\"Business\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/economicowl.com\/?p=2354\",\"url\":\"https:\/\/economicowl.com\/?p=2354\",\"name\":\"Eli Lilly Acquires Orna to Expand Cancer Technology - Economic Owl\",\"isPartOf\":{\"@id\":\"https:\/\/economicowl.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/economicowl.com\/?p=2354#primaryimage\"},\"image\":{\"@id\":\"https:\/\/economicowl.com\/?p=2354#primaryimage\"},\"thumbnailUrl\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/eli-lilly-acquires-orna-to-expand-cancer-technology.jpg\",\"datePublished\":\"2026-02-20T16:33:14+00:00\",\"dateModified\":\"2026-02-20T16:33:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/economicowl.com\/?p=2354#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/economicowl.com\/?p=2354\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/economicowl.com\/?p=2354#primaryimage\",\"url\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/eli-lilly-acquires-orna-to-expand-cancer-technology.jpg\",\"contentUrl\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/eli-lilly-acquires-orna-to-expand-cancer-technology.jpg\",\"width\":1000,\"height\":667,\"caption\":\"eli-lilly-acquires-orna-to-expand-cancer-technology\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/economicowl.com\/?p=2354#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/economicowl.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly Acquires Orna to Expand Cancer Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/economicowl.com\/#website\",\"url\":\"https:\/\/economicowl.com\/\",\"name\":\"Economic Owl\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/economicowl.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/economicowl.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/economicowl.com\/#organization\",\"name\":\"Economic Owl\",\"url\":\"https:\/\/economicowl.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/economicowl.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Economic-Owl.png\",\"contentUrl\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Economic-Owl.png\",\"width\":800,\"height\":150,\"caption\":\"Economic Owl\"},\"image\":{\"@id\":\"https:\/\/economicowl.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/economicowl.com\/#\/schema\/person\/47aea2855bc9394f42185505c66c542c\",\"name\":\"Sarah Romano\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/economicowl.com\/#\/schema\/person\/image\/ab66eea25b4d3630d971b39a51a50053\",\"url\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Sarah-Romano-1.png\",\"contentUrl\":\"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Sarah-Romano-1.png\",\"caption\":\"Sarah Romano\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eli Lilly Acquires Orna to Expand Cancer Technology - Economic Owl","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/economicowl.com\/?p=2354","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly Acquires Orna to Expand Cancer Technology - Economic Owl","og_description":"Deal adds in-body cell engineering platform Eli Lilly announced an agreement to acquire Orna Therapeutics for up to $2.4 billion in cash, advancing its push into next-generation cancer and immunology treatments. The transaction gives the U.S. drugmaker access to a technology designed to enable patients\u2019 own cells to generate therapies directly inside the body, avoiding [&hellip;]","og_url":"https:\/\/economicowl.com\/?p=2354","og_site_name":"Economic Owl","article_published_time":"2026-02-20T16:33:14+00:00","article_modified_time":"2026-02-20T16:33:15+00:00","og_image":[{"width":1000,"height":667,"url":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/eli-lilly-acquires-orna-to-expand-cancer-technology.jpg","type":"image\/jpeg"}],"author":"Sarah Romano","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sarah Romano","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/economicowl.com\/?p=2354#article","isPartOf":{"@id":"https:\/\/economicowl.com\/?p=2354"},"author":{"name":"Sarah Romano","@id":"https:\/\/economicowl.com\/#\/schema\/person\/47aea2855bc9394f42185505c66c542c"},"headline":"Eli Lilly Acquires Orna to Expand Cancer Technology","datePublished":"2026-02-20T16:33:14+00:00","dateModified":"2026-02-20T16:33:15+00:00","mainEntityOfPage":{"@id":"https:\/\/economicowl.com\/?p=2354"},"wordCount":395,"publisher":{"@id":"https:\/\/economicowl.com\/#organization"},"image":{"@id":"https:\/\/economicowl.com\/?p=2354#primaryimage"},"thumbnailUrl":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/eli-lilly-acquires-orna-to-expand-cancer-technology.jpg","articleSection":["Business"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/economicowl.com\/?p=2354","url":"https:\/\/economicowl.com\/?p=2354","name":"Eli Lilly Acquires Orna to Expand Cancer Technology - Economic Owl","isPartOf":{"@id":"https:\/\/economicowl.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/economicowl.com\/?p=2354#primaryimage"},"image":{"@id":"https:\/\/economicowl.com\/?p=2354#primaryimage"},"thumbnailUrl":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/eli-lilly-acquires-orna-to-expand-cancer-technology.jpg","datePublished":"2026-02-20T16:33:14+00:00","dateModified":"2026-02-20T16:33:15+00:00","breadcrumb":{"@id":"https:\/\/economicowl.com\/?p=2354#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/economicowl.com\/?p=2354"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicowl.com\/?p=2354#primaryimage","url":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/eli-lilly-acquires-orna-to-expand-cancer-technology.jpg","contentUrl":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/eli-lilly-acquires-orna-to-expand-cancer-technology.jpg","width":1000,"height":667,"caption":"eli-lilly-acquires-orna-to-expand-cancer-technology"},{"@type":"BreadcrumbList","@id":"https:\/\/economicowl.com\/?p=2354#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/economicowl.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly Acquires Orna to Expand Cancer Technology"}]},{"@type":"WebSite","@id":"https:\/\/economicowl.com\/#website","url":"https:\/\/economicowl.com\/","name":"Economic Owl","description":"","publisher":{"@id":"https:\/\/economicowl.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/economicowl.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/economicowl.com\/#organization","name":"Economic Owl","url":"https:\/\/economicowl.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicowl.com\/#\/schema\/logo\/image\/","url":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Economic-Owl.png","contentUrl":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Economic-Owl.png","width":800,"height":150,"caption":"Economic Owl"},"image":{"@id":"https:\/\/economicowl.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/economicowl.com\/#\/schema\/person\/47aea2855bc9394f42185505c66c542c","name":"Sarah Romano","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/economicowl.com\/#\/schema\/person\/image\/ab66eea25b4d3630d971b39a51a50053","url":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Sarah-Romano-1.png","contentUrl":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Sarah-Romano-1.png","caption":"Sarah Romano"}}]}},"authors":[{"term_id":115,"user_id":3,"is_guest":0,"slug":"fj5k9aslfkjshh2","display_name":"Sarah Romano","avatar_url":{"url":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Sarah-Romano-1.png","url2x":"https:\/\/economicowl.com\/wp-content\/uploads\/2026\/02\/Sarah-Romano-1.png"},"0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/posts\/2354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2354"}],"version-history":[{"count":1,"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/posts\/2354\/revisions"}],"predecessor-version":[{"id":2355,"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/posts\/2354\/revisions\/2355"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=\/wp\/v2\/media\/2349"}],"wp:attachment":[{"href":"https:\/\/economicowl.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2354"},{"taxonomy":"tmauthors","embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftmauthors&post=2354"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/economicowl.com\/index.php?rest_route=%2Fwp%2Fv2%2Fppma_author&post=2354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}